result, page-49

Here's a link to the Morgan's Healthcare weekly round up.

https://soundcloud.com/morgans-financial-limited/under-the-microscope-wrap-week-ending-22-november-2019

Friday's fall was most likely on the back of NAN being mentioned as part of a overvalued cohort of biotech stocks at the Sohn Hearts & Minds conference. Passive ETF's usually have algo's built in which react to certain "key words" and I think the selling was mainly an ETF dump. These types of sell downs provide an excellent opportunity for professional active investors to step up and get their fill.

I agree with the analyst's at Morgan's that the market has elected to look past the delay in the launch of the new product.

It's a structural growth business with a very large addressable market. Great management team with strong track record who are reinvesting heavily into pivot into different markets.

I think someone mentioned this in an earlier post, but the best way to look at NAN and the investment thesis is over a 5 years period. Believe there will be some great returns available for shareholders.